Bladder Cancer

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

ctDNA Helped Predict Response, Survival After Durvalumab in Lung, Bladder Cancer

ctDNA Helped Predict Response, Survival After Durvalumab in Lung, Bladder Cancer

By

Analyzing ctDNA following drug treatment could help identify nonresponders to immunotherapy.

MicroRNA Signature in Urine May Predict Presence of Bladder Cancer

MicroRNA Signature in Urine May Predict Presence of Bladder Cancer

By

Researchers found a microRNA signature in urine that can predict the presence of bladder cancer, advancing the idea of a noninvasive diagnostic test.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Role of miR-125a-5p Clarified in Bladder Cancer

Role of miR-125a-5p Clarified in Bladder Cancer

By

Researchers clarified the role of miR-125a-5p in bladder cancer, showing that it inhibits bladder cancer progression by targeting oncogene FUT4.

Bladder Cancer Clinical Features Linked to <i>EGFR</i> and </i>HER2</i> Expression

Bladder Cancer Clinical Features Linked to EGFR and HER2 Expression

By

A retrospective study found EGFR and HER2 overexpression associated with clinical features, such as tumor stage and tumor recurrence, in bladder cancer tissue.

Bladder Cancer Risk Higher With Radiation Therapy for Prostate Cancer

Bladder Cancer Risk Higher With Radiation Therapy for Prostate Cancer

By

In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Bladder Cancer Surveillance Not Aligned With Risk: Study of VA Facilities

Bladder Cancer Surveillance Not Aligned With Risk: Study of VA Facilities

By

Patients at VA facilities with high-risk early-stage bladder cancer tend to have cystoscopic surveillance at frequencies similar to those with low-risk disease.

Certain Muscle-Invasive Bladder Cancer Subtypes Do Not Respond to Neoadjuvant Cisplatin

Certain Muscle-Invasive Bladder Cancer Subtypes Do Not Respond to Neoadjuvant Cisplatin

By

Treatment with NAC did not transform the prevailing subtype in bladder cancer — instead, shifts in cancer subtype were attributed to tumor plasticity.

Later-Line Treatments for Metastatic Urothelial Carcinoma of the Bladder

Later-Line Treatments for Metastatic Urothelial Carcinoma of the Bladder

By

Researchers propose a treatment algorithm to clarify treatment options beyond the first line for metastatic urothelial carcinoma of the bladder.

Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer

Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer

By

BCG shortages did not appear to influence the incidence of radical cystectomy, but evidence of drug rationing was revealed.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

Stromal Cells Found to Act as Tumor Bodyguards in Bladder Cancer

Stromal Cells Found to Act as Tumor Bodyguards in Bladder Cancer

By

Gene expression of a biomarker linked to malignancies, found in stromal cells surrounding a tumor — not the tumor cells themselves — appears to prevent the action of checkpoint blockade.

Neoadjuvant Chemotherapy Before Radical Cystectomy May Improve Outcomes in Bladder Cancer

Neoadjuvant Chemotherapy Before Radical Cystectomy May Improve Outcomes in Bladder Cancer

By

Researchers assess the outcomes of 5517 patients with bladder cancer who underwent radical cystectomy with or without neoadjuvant radiotherapy or chemotherapy.

Neoadjuvant ddMVAC May Lead to Improved Treatment Response in Bladder Cancer

Neoadjuvant ddMVAC May Lead to Improved Treatment Response in Bladder Cancer

By

Previous studies showed that ddMVAC is well tolerated, but how it compares with gemcitabine plus cisplatin in regard to cancer control and survival outcomes requires further investigation.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer

Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer

By

A reanalysis suggested that an instillation of chemotherapy immediately after surgery may benefit all patients with non-muscle-invasive bladder cancer.

Approximately Two-Thirds of Patients With Stage IV Bladder Cancer Remain Untreated

Approximately Two-Thirds of Patients With Stage IV Bladder Cancer Remain Untreated

By

Patients in the SEER-Medicare database with stage IV bladder cancer were found to be less likely to receive chemotherapy than similar cohorts in earlier studies.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Robot-Assisted Cystectomy May Lead to Good Surgical, Oncologic Outcomes in Bladder Cancer

Robot-Assisted Cystectomy May Lead to Good Surgical, Oncologic Outcomes in Bladder Cancer

By

With the advent of minimally invasive surgery programs, robotic-assisted radical cystectomy is becoming a point of interest for bladder cancer.

Factors Associated With Locoregional Recurrence in Muscle-Invasive Bladder Cancer

Factors Associated With Locoregional Recurrence in Muscle-Invasive Bladder Cancer

By

A better understanding of the factors associated with locoregional recurrence and focused adjuvant therapeutic strategies may lead to enhanced oncologic outcomes.

Bladder Cancer Survival Better Among Married Patients

Bladder Cancer Survival Better Among Married Patients

By

Widowed patients with bladder urothelial carcinoma have the worst 5-year cancer-specific survival rates among unmarried patients.

Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer

Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer

By

Evidence for the impact of obesity on outcomes for bladder cancer have been conflicting and require further study.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs